Table 3.
Generalized linear mixed models of associations between transitions into ART adherence and transitions onto OAT among HIV-positive people reporting daily or more frequent opioid use in Vancouver, Canada (2005–2017; N = number of observations)
| Characteristic | Concurrent transitions into ART adherence N = 3378 |
Lagged† transitions into ART adherence N = 2471 |
Forward-lagged‡ transitions into ART adherence N = 2522 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||
| Bivariable cOR (95% CI) | Multivariable aOR (95% CI) | Bivariable cOR (95% CI) | Multivariable aOR (95% CI) | Bivariable cOR (95% CI) | Multivariable aOR (95% CI) | |||||||
|
| ||||||||||||
| Transitions into ART adherence | 0.75 (0.47–1.18) | 0.75 (0.47–1.20) | 1.45 (0.93–2.25) | 1.28 (0.81–2.04) | 1.33 (0.85–2.07) | 1.31 (0.84–2.06) | ||||||
| Older age (per 10 years older) | 0.66 (0.57–0.76) | *** | 0.71 (0.60–0.84) | *** | 0.66 (0.57–0.76) | *** | 0.73 (0.59–0.89) | ** | 0.66 (0.57–0.76) | *** | 0.59 (0.48–0.72) | *** |
| Male | 0.87 (0.69–1.11) | – | 0.87 (0.69–1.11) | – | 0.87 (0.69–1.11) | – | ||||||
| White ethnicity | 0.71 (0.56–0.90) | ** | – | 0.71 (0.56–0.90) | ** | – | 0.71 (0.56–0.90) | ** | – | |||
| ≥ High school educationa | 0.92 (0.72–1.18) | – | 0.92 (0.72–1.18) | – | 0.92 (0.72–1.18) | – | ||||||
| Recent incarcerationa | 1.61 (1.08–2.40) | * | – | 1.61 (1.08–2.40) | * | – | 1.61 (1.08–2.40) | * | – | |||
| Homelessnessa | 2.17 (1.67–2.84) | *** | 1.61 (1.13–2.28) | ** | 2.17 (1.67–2.84) | *** | – | 2.17 (1.67–2.84) | *** | – | ||
| Regular employmenta | 0.73 (0.51–1.06) | – | 0.73 (0.51–1.06) | – | 0.73 (0.51–1.06) | – | ||||||
| Informal or illegal income generationa | 1.42 (1.12–1.81) | ** | – | 1.42 (1.12–1.81) | ** | – | 1.42 (1.12–1.81) | ** | – | |||
| Public injectinga | 1.50 (1.16–1.94) | ** | – | 1.50 (1.16–1.94) | ** | – | 1.50 (1.16–1.94) | ** | – | |||
| Binge drug usea | 1.29 (1.02–1.64) | * | – | 1.29 (1.02–1.64) | * | – | 1.29 (1.02–1.64) | * | – | |||
| Syringe sharinga | 2.40 (1.37–4.22) | ** | – | 2.40 (1.37–4.22) | ** | – | 2.40 (1.37–4.22) | ** | – | |||
| Pipe sharinga | 1.37 (1.06–1.78) | * | – | 1.37 (1.06–1.78) | * | – | 1.37 (1.06–1.78) | * | – | |||
| Injecting alonea | 1.17 (0.91–1.50) | – | 1.17 (0.91–1.50) | – | 1.17 (0.91–1.50) | – | ||||||
| CD4 cell counts (per 100 cell/mm3 increase) | 0.93 (0.88–0.98) | ** | – | 0.93 (0.88–0.98) | ** | – | 0.93 (0.88–0.98) | ** | 0.90 (0.84–0.97) | ** | ||
95% CI: 95% confidence interval, aOR: adjusted odds ratio, ART: antiretroviral therapy, cOR: crude odds ratio, HIV: human immunodeficiency virus, OAT: opioid agonist therapy
*
p < 0.05
**
p < 0.01
***
p < 0.001
†
ART engagement preceding transitions onto OAT
‡
Transitions onto OAT preceding ART engagement
a
Describes behaviours or exposures in the past 6 prior to interview